Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Cerilliant
AstraZeneca
Fish and Richardson
US Army
Healthtrust
Deloitte
UBS
QuintilesIMS

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,767,223

« Back to Dashboard

Which drugs does patent 7,767,223 protect, and when does it expire?

Patent 7,767,223 protects OZURDEX and is included in one NDA.

This patent has fifteen patent family members in ten countries.
Summary for Patent: 7,767,223
Title:Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use
Abstract:Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
Inventor(s): Wong; Vernon G. (Menlo Park, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:11/180,079
Patent Claim Types:
see list of patent claims
Use; Compound; Delivery; Device;

Drugs Protected by US Patent 7,767,223

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan OZURDEX dexamethasone IMPLANT;INTRAVITREAL 022315-001 Jun 17, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,767,223

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,043,628 Methods for reducing edema ➤ Subscribe
6,699,493 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor ➤ Subscribe
8,828,446 Method for reducing transplant rejection in the eye and intraocular implants for use therefor ➤ Subscribe
7,033,605 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor ➤ Subscribe
8,071,120 Methods for treating neovascularization and intravitreal implants ➤ Subscribe
7,846,468 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor ➤ Subscribe
7,625,582 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor ➤ Subscribe
9,592,242 Methods for treating edema in the eye and intraocular implants for use therefor ➤ Subscribe
8,088,407 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor ➤ Subscribe
9,283,178 Methods for treating edema in the eye and intraocular implants for use therefor ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,767,223

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 306951 ➤ Subscribe
Australia 2002236495 ➤ Subscribe
Australia 2006201271 ➤ Subscribe
Australia 3649502 ➤ Subscribe
Brazil 0115772 ➤ Subscribe
Canada 2429998 ➤ Subscribe
Germany 60114229 ➤ Subscribe
Denmark 1339438 ➤ Subscribe
European Patent Office 1339438 ➤ Subscribe
European Patent Office 1550471 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
UBS
Deloitte
Daiichi Sankyo
Medtronic
Citi
Farmers Insurance
Novartis
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot